Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2020 Jul 29

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Pediatrica 2020 Jul 29

DOI: 10.23736/S0026-4946.20.05967-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Pidotimod in allergic diseases: the state of art

Sara MANTI , Giuseppe F. PARISI, Maria PAPALE, Salvatore LEONARDI

Pediatric Respiratory Unit, AOU Policlinico-Vittorio Emanuele, San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy


PDF


The rising incidence of allergic disease requires more specific, effective and safe therapeutic strategies. In this regard, several kinds of biologically active substances, commonly known as immunostimulants, have been introduced for the prevention and treatment of allergic diseases in pediatric population. Among the heterogeneous group of biologically active molecules to date available, Pidotimod is proved to be able to ameliorate both innate and adaptive immunity, and enhances the immune system properties often impaired in patients with allergic disorders.


KEY WORDS: Asthma; Atopic dermatitis; Children; Chronic spontaneous urticaria; Food allergy; Pidotimod; Rhinitis

top of page